Aurobindo Pharma is currently trading at Rs. 878.45, up by 12.25 points or 1.41% from its previous closing of Rs. 866.20 on the BSE.
The scrip opened at Rs. 865.00 and has touched a high and low of Rs. 884.90 and Rs. 859.10 respectively. So far 131903 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 930.00 on 29-Sep-2023 and a 52 week low of Rs. 397.30 on 03-Feb-2023.
Last one week high and low of the scrip stood at Rs. 922.00 and Rs. 859.10 respectively. The current market cap of the company is Rs. 50865.33 crore.
The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 40.74% and 7.42% respectively.
Aurobindo Pharma’s wholly owned subsidiary -- Eugia Pharma Specialities has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Testosterone Cypionate Injection USP 1,000 mg/10 mL (100 mg/mL) and 2,000 mg/10 mL (200 mg/mL) in Multi-Dose Vial and 200 mg/mL in Single-Dose Vial, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Depo-Testosterone Injection, 100 mg/mL and 200 mg/mL of Pfizer Inc. The product is expected to be launched in November 2023. The approved product has an estimated market size of $ 226.8 million for the twelve months ending August 2023, according to IQVIA.
This is the 169th ANDA approval (including 9 tentative approvals received) out of Eugia Pharma Speciality Group (EPSG) facilities, manufacturing both oral and sterile specialty products. Testosterone Cypionate Injection USP is indicated replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone, Primary hypogonadism (congenital or acquired) and Hypogonadotropic hypogonadism (congenital or acquired).
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1504.25 |
| Dr. Reddys Lab | 6263.70 |
| Cipla | 1406.25 |
| Zydus Lifesciences | 948.20 |
| Lupin | 1615.85 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
